Express²ion publishes video presentation

Hørsholm, Denmark, 05 September 2023 – Express²ion Biotech Holding AB’s affiliate Express²ion Biotechnologies ApS (“Express²ion”) announces that a filmed company presentation by CEO Bent U. Frandsen in which he presents an update on development of Express²ion’s business model, pipeline assets, recent developments, TO 8 warrant program and advancement towards key catalysts is now available on the company’s website.

In the presentation, Frandsen emphasized the importance of the clinical proof-of-concept and Phase III validation of the Company’s Express²™ technology within the Bavarian Nordic sponsored COVID-19 vaccine program, ABNCoV2. This proof-of-concept and validation is of paramount importance for Express²ion as it confirms the efficacy and safety of a product based on the Company’s technology for the first time in a pivotal clinical setting. This is a positive indicator for other vaccines based on the Express²™ technology.

Looking forward, Frandsen provided a concise overview of the Company’s potential future key catalysts, spanning both the near and long term:

- Monetization of focus pipeline assets, primarily ES2B-C001 through partnering and ABNCoV2 through license income
- Financing of new initiatives via non-dilutive financing
- Develop pipeline towards major value inflection points
- Strengthen the intellectual property rights and extract value from proprietary vaccine technologies
- Exploratory pipeline to build new internal assets in vaccine markets with unmet needs
- Focus on partnering activities for financing & risk sharing of assets

Finally, in the oral commentary it was clarified that the Company, with the recently announced strategic review, aims to extend its base case cash runway beyond 2024.

The presentation can be found on the Company’s investor website via the following link: [https://investor.expres2ionbio.com/presentations/](https://investor.expres2ionbio.com/presentations/)

Certified Adviser
Svensk Kapitalmarknadsgranskning AB

For further information about Express²ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
Email: investor@expres2ionbio.com

About Express²ion
Express²ion Biotechnologies ApS is a fully owned Danish subsidiary of Express²ion Biotech Holding AB with company register number 559033-3729. Express²ion has developed a unique technology platform, Express², for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. Express² is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. Express²ion develops novel VLP based vaccines in association with AdaptVac ApS, of which Express²ion owns 34%. For additional information, please visit [www.expres2ionbio.com](http://www.expres2ionbio.com).